Squawk on the Street Cramer's Morning Take: Eli Lilly 5/16/25
May 16, 2025
The discussion dives into the competitive dynamics of the pharmaceutical industry, showcasing why Eli Lilly's injectables outperform rivals like Wagovi and Ozempic. Insight is provided on Eli Lilly's recent stock performance and strategic advantages in comparison to Novo Nordisk. A leadership change at Novo Nordisk adds intrigue to the market positioning of these companies. Overall, it paints a picture of evolving consumer medication choices and the challenges major pharmaceutical players face.
AI Snips
Chapters
Transcript
Episode notes
Eli Lilly Surpasses Novo Nordisk
- Eli Lilly has caught up and surpassed Novo Nordisk in weight loss drug development and manufacturing.
- Lilly's manufacturing moat and the focus on a pill form give it a competitive edge over Novo Nordisk's injectables.
Pharma Stocks' Mixed Outlook
- Pharma stocks, including Abbott and Bristol-Myers, have faced recent challenges but still show potential.
- AbbVie's new Botox formula will deliver faster results, improving patient experience significantly.